NCT06679985 2026-04-13
A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma
Coherus Oncology, Inc.
Phase 2 Active not recruiting
Clinical Trials
12 trialsNCT05888402 2026-02-27
InTRist
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Active not recruiting
NCT06416696 2026-01-02
Toripalimab for High-risk Locally Advanced Cervical Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Active not recruiting
NCT06584435 2025-12-19
TUORA
Tianjin Medical University Second Hospital
Phase 2 Active not recruiting
NCT06293690 2025-12-18
Toripalimab Combined With SBRT for NSCLC
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Active not recruiting
NCT05975307 2025-12-01
BCIRT-01
Sun Yat-sen University
Phase 2 Active not recruiting
NCT07047001 2025-07-09
Vorolanib Monotherapy or in Combination With Toripalimab as Adjuvant Therapy for Patients With Intermediate-high Risk of Recurrence in Renal Cell Carcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Active not recruiting
NCT04517214 2025-04-02
Comparing Chemotherapy With/Without Toripalimab For Primary Metastatic Nasopharyngeal Carcinoma
Fudan University
Phase 2 Active not recruiting
NCT06717464 2024-12-05
Toripalimab Combined With Capecitabine as Postoperative Adjuvant Therapy for Patients With Resectable Advanced Extrahepatic Biliary Tract Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Active not recruiting
NCT04418154 2024-05-21
NeoTENNIS
Fudan University
Phase 2 Active not recruiting
NCT04301557 2024-04-23
PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer
Sun Yat-sen University
Phase 2 Active not recruiting
NCT04304248 2021-05-06
NeoTAP01
Sun Yat-sen University
Phase 2 Active not recruiting